Conference Proceedings
Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma
Michael E Feigin, Tyler Garvin, Peter Bailey, Nicola Waddell, David K Chang, Shimin Shuai, Steven Gallinger, John D McPherson, Sean M Grimmond, Ekta Khurana, Lincoln D Stein, Andrew V Biankin, Michael C Schatz, David A Tuveson
CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2016
Abstract
Abstract Pancreatic ductal adenocarcinoma (PDA) is a highly lethal malignancy with a 5-year survival rate of 6%, due in part to therapy resistance and late stage at diagnosis. A detailed understanding of the molecular alterations underlying PDA is required to uncover mechanisms of tumorigenesis and enable development of more effective therapies. As such, large-scale exome sequencing efforts have revealed genes (KRAS, TP53, CDKN2A, SMAD4) and pathways (Wnt/Notch, TGFβ, axon guidance, cell adhesion) important for PDA progression. However, the exome comprises less than 2% of the human genome. Whole-genome sequencing analyses have uncovered a somatic mutation rate of 1 mutation pe..
View full abstract